Form: CORRESP

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

June 21, 2024

 

FIBROBIOLOGICS, INC.

455 E. Medical Center Blvd.

Suite 300

Houston, Texas 77598

 

June 21, 2024

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

 

Attention: Doris Stacey Gama

 

  RE: FibroBiologics, Inc. (the “Company”)
    Registration Statement on Form S-1
    File No. 333-280303

 

Dear Mrs. Gama:

 

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-280303) be accelerated by the Securities and Exchange Commission to 5:00 p.m. Washington D.C. time on June 25, 2024, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.

 

We request that we be notified of such effectiveness by a telephone call to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328 of Norton Rose Fulbright (US) LLP, and that such effectiveness also be confirmed in writing.

 

  Very truly yours,
     
  FibroBiologics, Inc.
     
  By: /s/ Mark Andersen
  Name: Mark Andersen
  Title: Chief Financial Officer